Jynneos + MVA-BN (Quail)
Phase 2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Monkeypox (Mpox)
Conditions
Monkeypox (Mpox)
Trial Timeline
Oct 27, 2025 → Oct 31, 2026
NCT ID
NCT07199569About Jynneos + MVA-BN (Quail)
Jynneos + MVA-BN (Quail) is a phase 2 stage product being developed by Bavarian Nordic for Monkeypox (Mpox). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07199569. Target conditions include Monkeypox (Mpox).
What happened to similar drugs?
0 of 2 similar drugs in Monkeypox (Mpox) were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07199569 | Phase 2 | Recruiting |
Competing Products
5 competing products in Monkeypox (Mpox)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| BNT166a | BioNTech | Phase 1/2 | 33 |
| BNT166a | BioNTech | Phase 2 | 39 |
| MVA-BN | Bavarian Nordic | Phase 2 | 36 |
| MVA-BN standard regimen + MVA-BN half-dose regimen | Bavarian Nordic | Phase 3 | 44 |
| JYNNEOS (Liquid Formulation) + JYNNEOS (Lyophilized Formulation) | Bavarian Nordic | Phase 3 | 41 |